Abstract
Skin melanoma is a highly aggressive malignant neoplasm, the treatment of disseminated forms of which remains a serious problem, despite recent advances in the development of medical drugs based on the inhibition of the BRAF oncogene as well as on the basis of immune response regulators [1]. In addition, the question of identifying prognostic markers of metastasis and diagnostic markers of skin melanoma remains relevant. Despite advances in understanding the pathogenesis of melanoma and the development of various therapies aimed at immune checkpoints, the patient survival remains low in the progressing metastatic disease [2]. Targeted therapy and immune checkpoint inhibitors are used in the treatment of metastatic melanoma.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
